Palm Beach Gardens, FL, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for degenerative eye diseases today announced the engagement of Golden Eagle Capital Advisors, Inc (“GECA”), a financial advisory group based in Dubai as the exclusive agent and strategic advisor to the company.

About Golden Eagle Capital Advisors, Inc. https://geca-us.com/

GOLDEN EAGLE CAPITAL ADVISORS, INC. (GECA), a unit of Emintad, is an international Investment Bank and Wealth Management firm dedicated to providing the highest quality investment opportunities for institutional, private and retail clients.

The GECA Group, uniquely positioned, has developed a place where opportunities are created, and results are achieved by dynamic and experienced professionals.

Today the GECA group, to be close to its clients, can rely on the coordinated activity of two different headquarters, Dubai and New York, with its representative office in Hong Kong and alliances in Milan and London. We can offer to our clients a comprehensive suite of bespoke investment and financial advisory solutions complemented by a personalized red-carpet banking experience; facilitating access to capital, and identifying investment opportunities.

All the members of the group are dedicated to grant a world class experience in investment - financial advisory and wealth management services. Strategically aligned, we provide solutions going over and beyond traditional services.

Future Curative Biotechnology Press Releases and Updates

Interested investors and shareholders can be notified of future press releases and industry updates by e-mailing ir@curativebiotech.com

About Curative Biotechnology, Inc. http://curativebiotech.com

Curative Biotechnology, Inc. (Curative Biotech) is a development stage biomedical company focused on novel therapies for rare diseases. The Company is identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech currently has ongoing programs in three (3) different therapeutic areas: degenerative eye disease, infectious disease, and neuro oncology. The Company is now concentrating its energy and resources on its degenerative eye disease platform, based on a worldwide exclusive license from the National Eye Institute (NEI) at the National Institutes of Health (NIH). The first therapeutic in development on this platform is a Metformin Reformulation targeting the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD) disease with the goal of being in the clinic in 2025 for a first in human trial of the metformin-based eye drop. The trial will be conducted under a Cooperative Research and Development Agreement (CRADA) with the NEI.